6-(3,4-Dichlorophenyl)hexan-1-ol | 1026470-87-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 6-(3,4-Dichlorophenyl)hexan-1-ol
• CAS: 1026470-87-0
• 化学式: C₁₂H₁₆Cl₂O
• 分子量: 247.164
• InChiKey: YBJXVWKKWUOUST-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  6-(3,4-Dichlorophenyl)hexan-1-ol 在 potassium dihydrogenphosphate 、 N-溴代丁二酰亚胺(NBS) 、 sodium methylate 、 三苯基膦 作用下， 以 乙醚 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 38.59h， 生成 Methyl 3-cyano-4-[6-(3,4-dichlorophenyl)hexylsulfanyl]-3-hydroxybutanoate
  参考文献：
  名称：

  ATP-Citrate Lyase as a Target for Hypolipidemic Intervention. Design and Synthesis of 2-Substituted Butanedioic Acids as Novel, Potent Inhibitors of the Enzyme

  摘要：

  ATP-citrate lyase is the primary enzyme responsible for the synthesis of cytosolic acetyl-CoA in many tissues. Inhibitors of the enzyme represent a potentially novel class of hypolipidemic agent, which are anticipated to have combined hypocholesterolemic and hypotriglyceridemic properties. A series of a-substituted butanedioic acids have been designed and synthesized as inhibitors of the enzyme, The best compounds, 58, 68, 71, 74 have reversible K-i's in the 1-3 mu M range against the isolated rat enzyme, As representative of this compound class, 58, has been shown to exert its inhibitory action through a mainly competitive mechanism with respect to citrate and a noncompetitive one with respect to CoA. None of the inhibitors were able to inhibit cholesterol and/or fatty acid synthesis in HepG2 cells. This has been attributed to the adverse physicochemical properties of the molecules leading to a lack of cell penetration. Despite this, a lead structural class of compound has been identified with the potential for modification into potent, cell-penetrant, and efficacious inhibitors of ATP-citrate lyase.

  DOI：

  10.1021/jm960167w
• 作为产物：
  描述：

  3,4-二氯苯甲醛 在 platinum(IV) oxide 氢气 、 二异丁基氢化铝 、 dimsyl sodium 作用下， 以 甲醇 、 乙醚 、 二氯甲烷 为溶剂， 25.0 ℃ 、344.73 kPa 条件下， 反应 2.0h， 生成 6-(3,4-Dichlorophenyl)hexan-1-ol
  参考文献：
  名称：

  ATP-Citrate Lyase as a Target for Hypolipidemic Intervention. Design and Synthesis of 2-Substituted Butanedioic Acids as Novel, Potent Inhibitors of the Enzyme

  摘要：

  ATP-citrate lyase is the primary enzyme responsible for the synthesis of cytosolic acetyl-CoA in many tissues. Inhibitors of the enzyme represent a potentially novel class of hypolipidemic agent, which are anticipated to have combined hypocholesterolemic and hypotriglyceridemic properties. A series of a-substituted butanedioic acids have been designed and synthesized as inhibitors of the enzyme, The best compounds, 58, 68, 71, 74 have reversible K-i's in the 1-3 mu M range against the isolated rat enzyme, As representative of this compound class, 58, has been shown to exert its inhibitory action through a mainly competitive mechanism with respect to citrate and a noncompetitive one with respect to CoA. None of the inhibitors were able to inhibit cholesterol and/or fatty acid synthesis in HepG2 cells. This has been attributed to the adverse physicochemical properties of the molecules leading to a lack of cell penetration. Despite this, a lead structural class of compound has been identified with the potential for modification into potent, cell-penetrant, and efficacious inhibitors of ATP-citrate lyase.

  DOI：

  10.1021/jm960167w

文献信息

• A pharmaceutical preparation containing a 3-(2H)-furanone derivative for prevention and/or treatment of cataracts
  申请人：KIKKOMAN CORPORATION

  公开号：EP0737476A2

  公开（公告）日：1996-10-16

  In order to prevent or treat cataracts, present invention features 3(2H)-furanone derivatives having 3(2H)-furanone skeleton as a main structure and/or pharmaceutically acceptable salts thereof, pharmaceutical preparations containing the derivatives and/or the salts thereof, treatment methods of cataracts, and their use. The 3(2H)-furanone derivatives have excellent effects for the prevention and/or treatment of cataracts, for instance, senile cataracts caused by oxidation disorder. Particularly, the pharmaceutical preparations have good effect for the prevention and/or treatment of cataracts when they are administrated as ophtalmics.

  为了预防或治疗白内障，本发明的特点是以3(2H)-呋喃酮骨架为主要结构的3(2H)-呋喃酮衍生物和/或其药学上可接受的盐、含有这些衍生物和/或其盐的药物制剂、白内障的治疗方法及其用途。3(2H)-呋喃酮衍生物在预防和/或治疗白内障（例如，由氧化紊乱引起的老年性白内障）方面具有极佳的效果。特别是，这些药物制剂作为眼药使用时，对预防和/或治疗白内障具有良好的效果。
• US5698585A
  申请人：——

  公开号：US5698585A

  公开（公告）日：1997-12-16